After speaking with a Federal Trade Commission expert, RBC Capital says the expert does not see a barrier that would block the deal between Teva (TEVA) and Allergan (AGN). The expert says that the delay in the deal "is not unreasonable," according to RBC. The firm continues to expect the deal to close and it expects investors' confidence in Allergan to increase in the wake of the deal.

Vanda Pharmaceuticals "announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ(R) Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp." CEO Mihael H. Polymeropoulos stated: "We are disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law. However, we are pleased that our case has drawn attention to an area of law that has broad and significant implications in life sciences innovation."